Authors: Amnon A.Berger MD, PhD, Joseph Keefe BM, Ariel Winnick MA, Elasaf Gilbert BS, Jonathan P.Eskander MD, MBA, Cyrus Yazdi MD, Alan D.Kaye MD, PhD, Omar Viswanath MD, Ivan Urits MD Published in Science Direct August 2020 Abstract Background Fibromyalgia is a complex disease process that is as prevalent as it is poorly understood. Research into…
Author: Simon Erridge, Marie Miller, Tamara Gall, Antonio Costanzo, Barbara Pacchetti, and Mikael H. Sodergren Published in Mary Ann Liebert, Inc Publishers February 2020 Abstract Introduction: Cannabis-derived medicinal products (CDMPs) have antiemetic properties and in combination with opioids have synergistic analgesic effects in part signaling through the delta and kappa opioid receptors. The objective of this patient…
Author: Sarah S. Stitha, Jegason P.Diviant, Franco Brockelman, KeenanKeeling, BrandenHall, Storri Lucern, Jacob M.Vigil, Kathleen MacMillan MacMillan, Amanda Keddy, James Furlon Published in Science Direct July 2020 Abstract Objective: Few studies to date have measured the real-time effects of consumption of common and commercially available Cannabis products for the treatment of headache and migraine under naturalistic…
Author: Simon Erridge, Marie Miller, Tamara Gall, Antonio Costanzo, Barbara Pacchetti, and Mikael H. Sodergren Published in Mary Ann Liebert, Inc Publishers February 2020 Abstract Introduction: Cannabis-derived medicinal products (CDMPs) have antiemetic properties and in combination with opioids have synergistic analgesic effects in part signaling through the delta and kappa opioid receptors. The objective of this…
Author: Kevin M. Takakuwa, Frances S. Shofer, and Raquel M. Schears. Published in Mary Ann Liebert, Inc, Publishers February 2020 Abstract Introduction Medical cannabis laws have been passed in 33 U S States but cannabis remains federally illegal Eleven states additionally allow for adult use recreational Studies report and increase in Emergency Department ED use when…
Author: Kevin M. Takakuwa, Jeffrey Y. Hergenrather, Frances S. Shofer, and Raquel M. Schears Published in Mary Ann Liebert, Inc. Publishers January 2020 Abstract Objectives: To determine if cannabis may be used as an alternative or adjunct treatment for intermittent and chronic prescription opioid users. Design: Retrospective cohort study. Setting: A single-center cannabis medical practice site…
Author: Eric P. Baron, Philippe Lucas, Joshua Eades & Olivia Hogue Published in The Journal of Headache and Pain May 2018 Abstract Background Medicinal cannabis registries typically report pain as the most common reason for use. It would be clinically useful to identify patterns of cannabis treatment in migraine and headache, as compared to arthritis and…
Author: Eric P. Baron DO Published in HEADACHE Journal of Headache and face pain August 2018 Abstract Background Comprehensive literature reviews of historical perspectives and evidence supporting cannabis/cannabinoids in the treatment of pain, including migraine and headache, with associated neurobiological mechanisms of pain modulation have been well described. Most of the existing literature reports on the…
Authors: James Siklos-Whillans, Alia Bacchus, Laurie A. Manwell Published in International Journal of Mental Health and Addiction March 2020 Abstract Cannabis as a harm reduction strategy (HRS) is supported by evidence demonstrating its efficacy for pain relief and as a substitution for alcohol, illicit drugs, and pharmaceuticals. Animal models show cannabinoids reduce the effects of opiate…
Authors: Joshua Aviram, Yelena Vysotski, Paula Berman, Gil M Lewitus, Elon Eisenberg, David Meiri Published in MDPI June 2020 Background Medical cannabis (MC) treatment for migraine is practically emerging, although sufficient clinical data are not available for this indication. This cross-sectional questionnaire-based study aimed to investigate the associations between phytocannabinoid treatment and migraine frequency. Methods:…
Authors: Beth Weise and Adrianne R. Wilson-Poe Published in Mary Ann Leibert Inc. Publishers September 2018 Abstract Introduction: The opioid epidemic has become an immense problem in North America, and despite decades of research on the most effective means to treat opioid use disorder (OUD), overdose deaths are at an all-time high, and relapse remains…
Clinical and experimental rheumatology, January-February 2020
—
OBJECTIVES: To assess any clinical improvement attributable to the addition of medical cannabis treatment (MCT) to the stable (>3 months) standard analgesic treatment of fibromyalgia (FM) patients, the retention rate and any changes in the concomitant analgesic treatment over …